Design, Synthesis, and Evaluation of [ 68 Ga/ 177 Lu]-Labeled TSPO-Targeting Radioligands for PET/CT Diagnosis and Radionuclide Therapy of Brain Tumor
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.5c03527 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Xingkai Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substance and Function of Natural Medicines Institute of Materia Medica, Chinese Academy of Medical Sciences and Pe…. Hauptthemen laut MEDLINE: Brain Neoplasms, Receptors, GABA, Gallium Radioisotopes, Drug Design. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Municipal Health Commission Research Ward Excellence Clinical Research Program, Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China.
Abstract (Originalsprache)
The translocator protein (TSPO) has gained increasing attention in the diagnosis and treatment of brain cancers. Current TSPO-targeting radiotracers, predominantly labeled with 11C and 18F, limit the incorporation of emerging radionuclides into theranostic applications. In this study, we designed and synthesized four DOTA-conjugated TSPO-targeting precursors featuring various polyethylene glycol (PEG) linkers, which enabled straightforward and efficient labeling with 68Ga or 177Lu. In vitro and in vivo evaluations demonstrated that compared with [18F]FDG, all four 68Ga-labeled radioligands exhibited specific accumulation in glioblastoma in an orthotopic U87MG tumor-bearing mouse model. Among them, [68Ga]TSPO-1 displayed more favorable physicochemical properties, binding affinity, and, notably, the highest uptake in U87MG tumor tissues. Furthermore, [177Lu]TSPO-1 significantly inhibited U87MG tumor growth in the mouse model with satisfactory biosafety, implying its potent therapeutic potential for glioblastomas. In summary, this study develops DOTA-conjugated radioligands targeting TSPO and highlights the promise of [68Ga/177Lu]TSPO-1 for radiotheranostic applications in brain oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Xian Nong Tan Street, Beijing 100050,…
- Department of Molecular Imaging and Nuclear Medicine, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer…
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
- Department of Orthopaedics, The Second Affiliated Hospital of Soochow University, Suzhou 215031, China.
Förderung
- National Natural Science Foundation of China
- Beijing Municipal Health Commission Research Ward Excellence Clinical Research Program
- Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China
- Beijing Nova Program Interdisciplinary Cooperation Project
- Tianjin Key Medical Discipline Construction Project
- Tianjin Municipal Natural Science Foundation Joint Fund
- CAMS Innovation Fund for Medical Sciences
- Fundamental Research Funds for the Central Universities, Peking Union Medical College
Zitieren
APA
Wang, X., Zhang, S., Li, Y., Liu, C., Wu, J., Wu, Y., Hu, Q., Liu, W., Lu, Q., Hu, X., Dai, D., Zhang, Y., Zhang, Z., Wang, F., Wang, R., & Hu, K. (2026). Design, Synthesis, and Evaluation of [ 68 Ga/ 177 Lu]-Labeled TSPO-Targeting Radioligands for PET/CT Diagnosis and Radionuclide Therapy of Brain Tumor. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c03527
Vancouver
Wang X, Zhang S, Li Y, Liu C, Wu J, Wu Y, et al. Design, Synthesis, and Evaluation of [ 68 Ga/ 177 Lu]-Labeled TSPO-Targeting Radioligands for PET/CT Diagnosis and Radionuclide Therapy of Brain Tumor. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c03527
BibTeX
@article{Wang2026,
author = {Wang, Xingkai and Zhang, Siqi and Li, Yiming and Liu, Can and Wu, Jiang and Wu, Yuxuan and Hu, Qichen and Liu, Wenhao and Lu, Qingshuang and Hu, Xindan and Dai, Dong and Zhang, Yingzi and Zhang, Zhong and Wang, Feng and Wang, Rui and Hu, Kuan},
title = {Design, Synthesis, and Evaluation of [ 68 Ga/ 177 Lu]-Labeled TSPO-Targeting Radioligands for PET/CT Diagnosis and Radionuclide Therapy of Brain Tumor},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.5c03527}
}
EUVIMED